Growth Metrics

Opus Genetics (IRD) Receivables - Net (2019 - 2026)

Opus Genetics has reported Receivables - Net over the past 10 years, most recently at $1.7 million for Q1 2026.

  • Quarterly Receivables - Net fell 43.8% to $1.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Mar 2026, down 43.8% year-over-year, with the annual reading at $2.0 million for FY2025, 44.01% down from the prior year.
  • Receivables - Net was $1.7 million for Q1 2026 at Opus Genetics, down from $2.0 million in the prior quarter.
  • Over five years, Receivables - Net peaked at $10.1 million in Q3 2023 and troughed at $135000.0 in Q2 2023.
  • The 5-year median for Receivables - Net is $2.0 million (2024), against an average of $2.7 million.
  • The largest YoY upside for Receivables - Net was 905.93% in 2024 against a maximum downside of 81.67% in 2024.
  • A 5-year view of Receivables - Net shows it stood at $1.3 million in 2022, then decreased by 28.66% to $926000.0 in 2023, then soared by 284.77% to $3.6 million in 2024, then crashed by 44.01% to $2.0 million in 2025, then dropped by 13.23% to $1.7 million in 2026.
  • Per Business Quant, the three most recent readings for IRD's Receivables - Net are $1.7 million (Q1 2026), $2.0 million (Q4 2025), and $2.9 million (Q3 2025).